Publications by authors named "N M Navone"
Article Synopsis
- * Research on mice showed that Ra-223 rapidly reduces the number of osteoblasts (bone-forming cells) and this reduction can persist for at least 18 weeks, particularly affecting the trabecular bone regions.
- * The study highlights that while Ra-223 is effective against tumor-induced bone effects, it also negatively impacts normal bone health, suggesting that strategies to enhance bone health could help mitigate the associated fracture risks for patients.
Understanding the mechanisms underlying resistance is critical to improving therapeutic outcomes in patients with metastatic castration-resistant prostate cancer. Previous work showed that dynamic interconversions between epithelial-mesenchymal transition to mesenchymal-epithelial transition defines the phenotypic landscape of prostate tumors, as a potential driver of the emergence of therapeutic resistance. In this study, we use in vitro and in vivo preclinical MDA PCa patient-derived xenograft models of resistant human prostate cancer to determine molecular mechanisms of cross-resistance between antiandrogen therapy and taxane chemotherapy, underlying the therapeutically resistant phenotype.
View Article and Find Full Text PDFPurpose: Develop and deploy a robust discovery platform that encompasses heterogeneity, clinical annotation, and molecular characterization and overcomes the limited availability of prostate cancer models. This initiative builds on the rich MD Anderson (MDA) prostate cancer (PCa) patient-derived xenograft (PDX) resource to complement existing publicly available databases by addressing gaps in clinically annotated models reflecting the heterogeneity of potentially lethal and lethal prostate cancer.
Experimental Design: We performed whole-genome, targeted, and RNA sequencing in representative samples of the same tumor from 44 PDXs derived from 38 patients linked to donor tumor metadata and corresponding organoids.
Article Synopsis
- Prostate cancer research lacks diverse and widely used models, hindering progress in understanding and treating the disease.
- A workshop held in May 2023 brought together researchers to discuss the use and challenges of new patient-derived models such as xenografts and organoids.
- There is a call for expanding the variety of models, improving their testing conditions, ensuring reproducibility, and enhancing collaboration among research groups to better represent the complexities of prostate cancer.